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MDS   Myelodysplastic syndrome   
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Summary 
Background. Hemorrhagic complications are frequent and among the leading causes of 
death in patients with myelodysplastic syndromes (MDS). Not only thrombocytopenia, 
but also platelet function abnormalities contribute to bleeding tendency of MDS patients. 
However, no published studies comprehensively evaluated several parameters of platelet 
function, including the measurement of the platelet levels of cyclic AMP (cAMP), which 
is an effective inhibitor of platelet function. In this case-control study, we aimed to 
comprehensively assess in vitro platelet function of patients with MDS of any IPSS risk 
category. 
Methods. Patients diagnosed as MDS according to WHO guidelines and two control 
groups, primary Immune ThrombocytoPenia (ITP) patients and healthy subjects  were 
consecutively recruited. Platelet aggregation and secretion in platelet rich plasma (PRP) 
with platelet count >150x109/L were induced by adenosine diphosphate (ADP) (2µM), 
epinephrine (5µM), thrombin receptor-activating peptide (TRAP) (10µM), synthetic 
reactive peptide (SRP) (4 ng/mL) (Biodata, USA), collagen reactive peptide (CRP) 
0.1µg/mL (Farnardale lab, UK), Horm collagen (2µg/mL) and arachidonic acid (AA) (1 
mM) and measured by lumi-aggregometry. In addition,  the effect of Prostaglandin E1 
(PGE1) (0.1µM) was tested in collagen-induced platelet aggregation. Intraplatelet cAMP 
content was measured by an ELISA assay (Cayman, USA) in extracts of PRP containing 
theophylline (1 mM), incubated with PGE1 (1 or 0.1 µM) or Tyrode’s buffer alone for 2 
minutes. Differences among the three groups were analyzed by Kruskal-Wallis and 
Dunn's multiple comparisons test. Correlation was studied by Spearman's rank correlation 
analysis. 
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Results. 32 MDS (male=22), 26 ITP (male=12) patients, and 54 healthy subjects 
(male=26) were enrolled.  Platelet aggregation measured in PRP samples induced by all 
agonists was significantly lower in MDS patients than in both control groups, but there 
was no difference between ITP and healthy subjects. The platelet aggregates formation 
induced by collagen was significantly decreased in presence of PGE1 (0.1uM) in all 
groups. The extent of decrease was significantly higher in MDS patients than in the other 
two groups. MDS and ITP patients showed abnormal ATP release measured during 
aggregation induced by all agonists compared to controls. Intraplatelet cAMP production 
induced by PGE1 (0.1uM and 1 uM) were similar in MDS patients, ITP patients and 
healthy controls. However, when calculated as the ratio of cAMP increase after PGE1 
stimulation, both MDS and ITP groups showed significantly lower increase ratio than 
healthy subjects.  
Conclusion: The platelets dysfunction in MDS and ITP groups showed despaired 
aggregation and secretion, decreased intra-platelets granules contents, but with normal 
platelet surface receptors expression. Lower total cAMP level, and lower increase of 
cAMP ratiao (PRP – PPP)/PPP after adding of extra PGE1, may suggest that there could 
be dysfunctional maturation of platelets.
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1.1 Platelet 
1.1.1 Structure of platelets 
Human blood platelets are small, anucleated cells that play a critical role in hemostasis 
and thrombosis. Human platelets normally survive for approximately 10 days in the 
circulation. Normal human platelets are small and discoid in shape, the size is about 0.5 
× 3.0 μm, have a mean volume of 7–11 fL, and normally circulate in relatively high 
numbers between 150 and 400 × 10^9/L. 
1.1.2 Platelet function in primary haemostasis 
Their small disc shape enables platelets to marginate toward the edge of vessels so that 
the majority circulate adjacent to the vascular endothelial cells that line all blood vessels. 
Upon detection of vessel wall damage, they undergo rapid but controlled adhesion, 
activation, and aggregation to form a hemostatic plug and thus rapidly prevent blood 
loss. Endothelial cells produce a number of potent antiplatelet substances (e.g. nitric 
oxide, prostacyclin and CD39) that normally inhibit vessel wall–platelet interactions. 
Vessel wall damage exposes highly adhesive substrates [e.g. P selectin, Von Willebrand 
factor (VWF), collagen, and other extracellular matrix components], which result in a 
sequence of stepwise events resulting in the formation of a hemostatic plug1: 
1. Platelet adhesion. The process of platelet adhesion involves the interaction of 
receptors on the platelet membrane glycoprotein (GP) VI, GPIbα and GPIIb/IIIa, with 
its ligands in the like collagen, and VonWillebrand factor (vWF). As results of these 
interactions, a platelet activation process takes place that includes participation of one 
or more signal transduction pathways. 
2. Platelet aggregation and platelet procoagulant activity. Platelet activation triggers 
the synthesis and release of several autocrine and paracrine mediators, including 
adenosine diphosphate (ADP), thrombin, epinephrine, and thromboxane A2 (TXA2). 
ADP, TXA2 and thrombin activate platelets through their interaction with G protein-
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coupled receptors (GPCR), which activate multiple G protein–mediated signaling 
pathways to induce platelet-shape change, degranulation and integrin activation. Some 
GPCR are associated with G proteins (Gs) that stimulate adenilyly cyclase, thereby 
increasing the levels of cyclic AMP (cAMP), which inhibits platelet function: 
prostacuyclin and prostaglandin E1 are among the ligands that bind to Gs coupled 
receptors. 
Activated platelets also express negatively charged phospholipids on their surface, 
facilitating the local generation of thrombin, which not only further activates platelets, 
but also stabilizes the platelet plug through fibrin formation. In this manner, platelets 
contribute to sealing any areas of vessel wall damage. 
1.2 Myelodysplastic syndromes   
Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal disorders of 
the hematopoietic stem cell (HSC), characterized by peripheral cytopenias despite 
increased hematopoïetic precursors, resulting in anemia, neutropenia or 
thrombocytopenia. Patients are at increased risk of infection and bleeding. About 30% 
of MDS patients develop acute myeloid leukemia. Among the cytopenias, 
thrombocytopenia is a serious complication of ineffective hematopoiesis and is 
associated with worse overall survival. 
MDS is thought to result from the accumulation of genetic or epigenetic (such as 
promoter hypermethylation) lesions, occurring initially in an immature progenitor and 
leading to a proliferative advantage of the MDS clone over normal immature 
progenitors. Age-induced genetic, epigenetic, and immune-mediated changes in 
haemopoietic stem cells (HSC) lead to oligoclonal expansion of myelodysplastic stem 
cells, with defective differentiation, characterised by increased apoptosis of erythroid 
and myeloid progenitors 2 . Microenvironmental changes and immune deregulation 
contribute to this differentiation defect. MDS progenitors display abnormal terminal 
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differentiation and increased susceptibility to apoptosis, which may explain the clinical 
consequences of blast accumulation and peripheral cytopenias3. 
The median age at diagnosis is approximately 70 years. The incidence is 4 to 5 per 
100,000 persons per year. The etiology is generally unknown, the role of exposure to 
environmental chemical and physical mutagens is sometimes suspected. In 15 to 20% 
of cases, however, MDS are secondary (sMDS) to chemotherapy and/or radiotherapy 
for a prior illness. More rarely, they are secondary to exposure to benzene or other 
aromatic hydrocarbons, or products used in agriculture. 
Presence of dysplasia is the first key criterion for diagnosis and prognosis of MDS. A 
given lineage is considered dysplastic if two or more dysplastic features are found in > 
10% cells. Multilineage dysplasia (MD) is defined as the coexistence of dysplasias in 
two or more lineages. Blast cells excess is observed in about 40-60% of cases.  
Myeloblasts are consensually defined by a high nuclear/cytoplasmic ratio and diffuse 
chromatin pattern, can be "agranular" or "granular". MDS have received a variety of 
nomenclatures, until the first international classification by the French American British 
(FAB) group in 1982. This classification has been refined in 2001 then in 2008 by a 
WHO expert committee 4 , integrating novel prognostic factors in MDS, such as 
multilineage dysplasia. The marrow blast threshold of AML was lowered from 30% to 
20%. This classification also designed the term MDS/MPN (Myeloproliferative 
Neoplasm) to regroup a heterogeneous set of rare entities including chronic 
myelomonocytic leukemia (CMML), previously considered as a MDS. 
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Table 1.1. WHO classification for MDS 
Subtype Peripheral blood Bone marrow Relative 
Proportion  
Refractory cytopenia with unilineage dysplasia 
(RCUD) 
   
Refractory anaemia (RA) Anaemia, <1% blasts Unilineage erythroid dysplasia 
(in >10% cells), <5% blasts 
10–20 
 
Refractory neutropenia (RN) Neutropenia, <1% blasts Unilineage granulocytic 
dysplasia, <5% blasts 
<1 
 
Refractory thrombocytopenia  Thrombocytopenia, <1% blasts Unilineage megakaryocytic dysplasia, <5% 
blasts 
<1% 
Refractory anaemia with ring sideroblasts (RARS) Anaemia, no blasts Unilineage erythroid dysplasia, >15% erythroid 
precursors are ring sideroblasts, <5% blasts 
3–10% 
Refractory cytopenia with multilineage dysplasia 
(RCMD) 
Cytopenia(s), <1% blasts. No 
Auer rods 
Multilineage dysplasia +/. ring sideroblasts, <5% 
blasts. No Auer rods 
30% 
Refractory anaemia with excess blasts type 1 (RAEB-1) Cytopenia(s), 2–9% blasts. No 
Auer rods 
Unilineage or multilineage dysplasia, 5–9% 
blasts. No Auer rods 
40% 
Refractory anaemia with excess blasts type 2 (RAEB-2) Cytopenia(s), 5–19% blasts +/. 
Auer rods 
Unilineage or multilineage dysplasia, 10–19% 
blasts. +/. Auer rods 
 
Myelodysplastic syndrome associated with isolated 
del(5q) 
Anaemia Normal or high 
platelet count, <1% blasts 
5q31 deletion Anaemia, hypolobulated 
megakaryocytes, <5% blasts 
<5% 
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Myelodysplastic syndrome, unclassifiable (MDS-U) Cytopenia(s), <1% blasts Does not fit in other groups Rare 
Childhood myelodysplastic syndrome Pancytopenia <5% blasts <1% 
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BM biopsy first allows objective evaluation of BM cellularity, which physiologically 
declines with age. Application of a standardized age correction to cellularity brings the 
incidence of "hypoplastic" MDS from 29% to 7% 5 . Hypoplastic MDS raises the 
question of the differential diagnosis with aplastic anemia (AA). Features of MDS are 
the presence of circulating myeloblasts, megakaryocytic or granulocytic dysplasia. 
Other MDS criteria include abnormal sideroblasts, presence of two or more blast cell 
clusters. Clusters (3-5 cells) or aggregates (> 5 cells) of blasts cells away from endosteal 
or vascular niches, in the central portion of the BM have been dubbed "abnormally 
localized immature myeloid progenitors" (ALIP). ALIP have been proposed as 
diagnostic and prognostic markers.   
Immunohistochemistry with a CD34 antibody marks immature hematopoietic 
progenitors and megakaryocytes, and can be used to asses the blast percentage. 
However, some MDS have CD34- blasts: in those cases, CD117 has been proposed as 
a surrogate marker. Some authors have proposed that the presence of CD34+ cell 
clusters may better reflect prognosis than CD34+ cell percentage. 
Prognostic evaluation in MDS still largely relies on an International Prognostic Scoring 
System (IPSS) established on the basis of an international cohort of patients (IMRAW 
cohort) treated symptomatically and recently revised (IPSS-R)6. IPSS relies on number 
of cytopenias, marrow blast percentage and cytogenetic. Patients are regrouped into 
four risk categories (low, intermediate 1 and 2, and high). IPSS categories are often 
regrouped into lower-risk MDS (IPSS low and intermediate-1), and higher-risk MDS 
(IPSS intermediate-2 and high). Lower-risk MDS are patients with prolonged survival 
where the main objectives are to cope with chronic cytopenias notably anaemia, and to 
defer ASCT. On the other hand the treatment in higher-risk MDS should alter disease 
history and prolong survival. The approval of azacytidine in higher-risk underscores the 
importance of IPSS evaluation in all patients at diagnosis.  
According to the IPSS-R, 27% of the lower-risk MDS patients of the original IPSS are 
1.Introduction 
1 
reclassified as having a higher risk and they potentially need a more intensive treatment. 
Conversely18% of high-risk MDS patients, as defined by the original IPSS, are 
reclassified as low risk by the IPSS-R.  
Table 1.2. Comparation of items in IPSS with Revised IPSS (R-IPSS) 
IPSS R-IPSS 
Parameter Score Parameter Score 
Blastes  Blastes  
<5% 0 =<2% 0 
5-10% 0.5 2-5% 0.5 
15-20% 1.5 5-10% 1.5 
21-30% 2 >10% 2 
Cytogenetics  Cytogenetics  
Good 0 Very good 0 
Intermediate 0.5 Good 0.5 
Poor 2 Intermediate 2 
  Poor 3 
  Very poor 4 
  Hb  
  8-10 1 
  <8 1.5 
  ANC  
  <0.8 0.5 
  Platelts  
  50-100 0.5 
  <50 1 
Risk groups score OS Risk groups score OS 
Low 0 5.7 Very low =<1.5 8.8 
Int-1 0.5-1 3.5 Low 1.5-3 5.3 
Int-2 1.5-2 1.2 Int 3-4.5 3. 
High >2 0.4 High 4.5-6 1.6 
   Very high >6 0.8 
*OS: Overall Survival     ANC:  Absolute Neutrophil Count, 
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Table 1.3. Karyotype (IPSS-R) 
 
Proportion 
of patients 
(%) 
Karyotype Median 
survival 
(years) 
Time to 25% 
AML 
evolution 
(years) 
Very good 4% 
-Y, 
5.4 NR del(11q) 
Good 72% 
Normal, 
4.8 9.4 del(5q), 
del(12p), 
del(20q), 
double including 
del(5q) 
Intermediate 13% 
del(7q), 
2.7 2.5 +8, 
+19, 
i(17q), 
any other single or 
double 
independent clones 
Poor 4% 
-7, 
1.5 1.7 inv(3)/t(3q)/del(3q) 
double including -
7/ del(7q) 
Complex: 3 
abnormalities 
Very poor 7% 
Complex > 3 
abnormalities 0.7 0.7 
Treatment  
Treatment varies from symptomatic treatment of cytopenias, especially by transfusions 
for anemia, to allogeneic stem-cell transplantation. Treatment of patients with lower-
risk myelodysplastic syndromes includes growth factors and lenalidomide. Higher-risk 
patients are treated with hypomethylating agents and allogeneic stem-cell 
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Table1.4. Treatment 
Summary of Treatments for Thrombocytopenia in Myelodysplastic Syndromes  
Regimen class/drug category    
Platelet focused                                                                            Drug name
Androgens       Danazol 
Thrombopoietic growth factors  IL-11; IL-6; PEG-rHuMGDF  
General                  
Differentiation agents Azacitidine; decitabine          
Anti-TNFa factors Amifostine; etanercept; pentoxifylline  
Hematopoietic growth factors IL-3 
Immunosuppressive agents  Cyclosporine; ATG 
Retinoids  ATRA; 13-cis retinoic acid 
Angiogenic inhibitors  Arsenic trioxide; sirolimus 
Immunomodulatory agents  Lenalidomide; thalidomide 
Chemotherapy Cytosine arabinoside; Combination of 
topotecan, cytarabine, and idarubicin 
Farnesyl-transferase inhibitors Tipifarnib; lofarnib 
Vitamin D compounds Calcitriol 
Vitamin K2  Menatetrenone  
1.3 Immune thrombocytopenia 
Immune thrombocytopenia (ITP) is defined as isolated low platelet count 
(thrombocytopenia) with normal bone marrow and the absence of other causes of 
thrombocytopenia such as systemic lupus erythematosus, malignancy, and DIC. It 
causes an increased tendency to bleed8.  
The incidence of ITP is estimated at 50–100 new cases per million per year, with 
children accounting for half of that amount.  At least 70 percent of childhood cases 
will end up in remission within six months, even without treatment. Moreover, a third 
of the remaining chronic cases will usually remit during follow-up observation, and 
another third will end up with only mild thrombocytopenia (defined as a platelet count 
above 50*10^6/mL).  
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ITP is usually chronic in adults and the probability of durable remission is 20–40 
percent. The male to female ratio in the adult group varies from 1:1.2 to 1:1.7 in most 
age ranges and tends to widen with age (childhood cases are roughly equal for both 
sexes) and the median age at the diagnosis is about 60 years.[9] 
In approximately 60 percent of cases, antibodies against platelets can be detected. Most 
often these antibodies are against platelet membrane glycoproteins IIb-IIIa or Ib-IX, 
and are of the immunoglobulin G (IgG) type. 
In mild cases, only careful observation is required. In contrast, severe cases, especially 
if accompanied by bleeding manifestations, need treatment with corticosteroids, 
intravenous immunoglobulin, anti-D immunoglobulin, or other immunosuppressive 
drugs. Refractory ITP (not responsive to conventional treatment) may require 
splenectomy. 
1.4 Measurement methods for evaluating platelet function  
1.4.1Lumi-aggregometry measurement for platelet aggregation and secretion 
Of all the functional responses of platelets, aggregation is probably the mostly widely 
investigated.  Turbidimetric aggregometry in its modern form was initially described 
in the 1960s. Light is passed through a stirred turbid suspension of platelets9; the 
presence of the platelets in suspension causes the light to be scattered such that a 
reduced proportion of it passes directly through the platelet suspension unobstructed. 
The amount of transmitted light is recorded and provides a measure of the optical 
density of the platelet suspension. On addition of a proaggregatory stimulus, as the 
platelets aggregate, the optical density of the suspension is reduced. A typical curve for 
platelet aggregation recorded by LTA method showed in Figure 110.  
The unstimulated suspension of platelet-rich plasma (PRP) has a relatively high optical 
density (OD). Following addition of the agonist (A) the platelets aggregate, allowing 
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more light to pass through the suspension of platelets and resulting in a reduction in the 
optical density. Autologous platelet-poor plasma (PPP) provides the measured optical 
density equivalent to 100% aggregation as indicated by the calibration mark. The 
transient increase in optical density that is typically observed following addition of the 
agonist is commonly attributed to the phenomenon of platelet shape change.  
 
Figure1.1. Diagram of a typical turbidimetric aggregometry trace 
  
Figure1.2. Diagram of a typical lumi- aggregometry tracing:  
the upper tracings refer to platelet aggregation,  
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while the lower tracing refer to platelet secretion of ATP. 
During platelet aggregation, contents of platelet granules, such as ATP, can be secreted 
into the extracellular medium. In order to detect secreted ATP, the firefly luciferin-
luciferase system is used, because it produces a light output proportional to the ATP 
concentration in the extracellular medium.11. The firefly luciferin-luciferase system 
enables continuous monitoring of the ATP concentration, in parallel with platelet 
aggregation in the lumiaggregometer instrument, according to the following formula: 
ATP + D-luciferin + O2 →AMP + PPi + oxyluciferin + CO2 + light   (1.1) 
Studies on platelet aggregation and secretion in MDS patients  
According to literature, patients with MDS have no specific disorders of blood 
coagulation or fibrinolysis, but their bleeding time may be prolonged. There have been 
many reports of abnormalities of platelet function in MDS patients, the most common 
being reduced aggregation when upon stimulation by epinephrine or collagen. 
Individual patients are affected to variable degrees, and it is possible that various 
subpopulations of normal and abnormal cells coexist during the course of illness.  The 
following table shows a summary of studies on platelet aggregation in MDS patients.  
Table1.5. Studies of platelet aggregation in myelodysplastic syndromes 
No. Abnormal / No. Tested 
Ref. 
ADP Epinephrine Collagen Arach.acid Ristocetin 
0/2 2/2 1/2 - - Caen et al11 
1/1 - 1/1 - - Sultan et al12 
 6/6 6/6 6/6 - - Rahman et 
al13 
2/2 - 2/2 1/1 - Russell et al14 
7/14 12/14 12/14 - 7/14 Lintula et al15 
2/3 - 2/3 - 2/3 Tricot et al16 
6/6 6/6 4/6 - - Stuart17 
0/17 - 7/17 - 0/17 Pamphilon18 
5/18 9/18 11/18 3/18 7/18 Lintula et al 
13/23 15/23 4/23 11/23 5/23 Aliza 
Zeidman19 
  5/8   Blockmans 
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D20 
TOTAL      
29/69 
(42%) 
35/46(76%) 46/69(67%) 4/19(21%) 16/52(31%)  
These studies studied small patient populations and never measured platelet aggregation 
and secretion simultaneously. 
1.4.2 Platelet granules contents measurement 
In the resting state, platelet α-granules and dense granules are distributed throughout the 
platelet cytoplasm21. When platelets are activated, centralization of granules occurs. α-
granules secrete fibrinogen and VWF, adhesive proteins that mediate platelet-platelet and 
platelet-endothelial interactions. Components of the VWF receptor complex (GPIbα-IX-
V), the major receptor for fibrinogen (integrin αIIbβ3), and the collagen receptor (GPVI) 
are stored in α-granules. Although these receptors are also constitutively expressed on the 
platelet plasma membrane, an estimated one-half to two-thirds of αIIbβ3 and one-third or 
more of GPVI reside in α-granule membranes in resting platelets and are expressed 
following activation. Platelet α-granules contain a number of coagulation factors and co-
factors that participate in the coagulation process. Factors V, XI, and XIII each localize 
in α-granules and are secreted upon platelet activation. Platelet factor 4 (PF4) is a 
small cytokine belonging to the CXC chemokine family that is also known as chemokine 
(C-X-C motif) ligand 4 (CXCL4). This chemokine is released from alpha-granules of 
activated platelets during platelet aggregation, and promotes blood coagulation by 
moderating the effects of heparin-like molecules.  
δ-granules contain several molecules: ATP and ADP, serotonin, calcium, inorganic 
polyphosphate Platelets are the main storage site for serotonin in the human body. Normal 
platelets avidly take up serotonin from the blood stream and store it in the δ-granules, 
where it is protected from the action of mitochondrial monoamino oxidases.  
Patient with δ-Storage Pool Deficiency (δ-SPD) are characterized by mild to moderate 
bleeding diathesis (mucocutaneous bleeding, epistaxis, menorrhagia, easy brusing)22 , 
mildly to moderately prolonged bleeding time, abnormal platelet aggregation and 
secretion induced by several platelet agonists, and decreased content of δ-granules in 
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platelets and megakaryocytes. The platelet count is generally normal, although it may be 
slightly decreased in 20-40% of cases.  The storage pool contains more ADP than ATP, 
while the opposite is true for the metabolic pool. The normal ratio between total 
concentrations of ATP and ADP is 2.5:1: as a consequence this ratio is higher in patients 
with δ-SPD.  
In order to measure ADP, it is possible to use the luciferine-lucipherase reagent, which 
measures ATP (see above), in the presence of pyruvate kinase, which  catalyzes the 
transfer of a phosphate group from phosphoenolpyruvate (PEP) to ADP, yielding one 
molecule of pyruvate and one molecule of ATP. 
PEP + ADP Pyruvate + ATP                 (1.2) 
Figure 1.3 shows a typical tracing of nucleotide measurements in a platelet sample.  The 
first peak is generated by ATP in the sample, the second peak refers to an internal standard 
of ATP is added; the third peak is greeted by the appearance of ATO resulting from the 
conversion of ADP in the presence of PEP+PK. The last peak refers to additional Standard 
ATP added to the sample. 
 
Figure1.3 Tracings obtained during the measurement of ATP and ADP in platelet 
samples. 
 
ATP in 
sample 
I1 
ATP std  
 
I1+S1 
PEP and PK produce ATP 
from ADP in sample 
                      
Vmax 
ATP std 
    
   I2+S2 
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1.4.3 Flow cytometry 
Flow cytometry allows the analysis of multiple antigens in a single tube at a single cell 
level. Flow cytometry allows the rapid analysis of many thousands of individual cells per 
second as they pass through the focused beam of a laser light source. Reflected or 
refracted light is detected by photodiodes or photomultiplier tubes and translated into an 
electronic signal, which represents a measure of the cells’ size and granularity, 
respectively. This allows discrimination of different cell types with distinct morphological 
characteristics within a complex mixture such as whole blood, thus enabling analysis of 
the platelets. 
Flow cytometry is an accurate method for detecting and enumerating constitutively 
expressed platelet membrane glycoproteins23. The method can form part of a routine 
laboratory screening program for the diagnosis of patients with congenital platelet defects, 
to give a clear diagnosis of patients with severe, homozygous defects. Levels of receptors 
can also be measured in relation to gene polymorphisms and platelet function. The 
constitutively expressed platelet receptors can be measured in this way, provided they are 
present at a high enough density to reach the level of detection by flow cytometry.  
The most important antigens for platelets are the VWF binding receptor glycoprotein (GP) 
complex Ibα/β-IX-V (CD42a-d), the collagen binding receptor GPVI, and the platelet 
aggregation receptor alpha2b-beta3 (CD41/CD61) 24 . CD41 and CD61 are both or 
separately aberrant in Glanzmann Thrombasthenia (GT), an autosomal inherited platelet 
disorder. GPIX (CD42a) or GPIbα (CD42b) can be aberrant in the bleeding disorders 
Bernard-Soulier syndrome. Aberrant expression of CD62P has been reported in patients 
with α-storage pool disease (α-SPD).  
Measurement of glycoproteins on platelets can be carried out by single-color analysis in 
which the platelets are identified solely on the basis of their forward scatter (FS, a measure 
of cell size) and side scatter (SS, a measure of cell granularity), then analyzed for antigen 
expression. 
However, to ensure that all platelets are identified, and more importantly, to ensure that 
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any platelet-sized particles derived from other cells are eliminated from the analysis, a 
two-color approach can be used. In this case the sample is co-labeled with an antibody to 
a highly expressed, platelet-specific antigen and an antibody to the antigen being studied. 
The two antibodies are labeled with different fluorophores. 
Fluorescence measurement can be expressed either as the percentage of positive cells 
above a threshold set with an appropriate negative control, or as the mean or median 
fluorescence intensity (MFI) of a population of cells; the median is the more appropriate 
measure for an antigen that shows a non-Gaussian, or heterogeneous, distribution on the 
platelet population. Percentage positive data are used primarily to measure increased 
expression of an antigen that is not normally present on the platelet surface (e.g., an 
activation antigen), or to discriminate between populations of cells, whereas MFI is used 
to quantify the level of expression of an antigen that is constitutively expressed.   
1.4.4 Platelet TxA2 pathway 
Platelets synthesize prostaglandins when activated by thrombin or collagen, which 
promote liberation of arachidonic acid (AA) from platelet phospholipids by the enzyme, 
phospholiphase A2 and the subsequent synthesis of prostaglandin G2 (PGG2) AND 
PGH2 from AA by the enzyme cyclo-oxygenase25. PGH2 is the substrate for several 
synthases that generate a range of bioactive prostanoids such as PGD2, PGE2, PGI2 and 
TxA2. While almost all human tissue is capable of generating PGH2, its metabolite is 
tissue-specific and depends on the presence of tissue-specific enzyme. In platelets, 
thromboxane synthase (TXS) is responsible for the conversion of PGH2 into TxA2, a 
known strong platelet agonist (Figure 1). 
Once produced, TxA2 has a short half-life (30 seconds) and acts on neighboring cells via 
autocrine or paracrine systems. TxA2 undergoes rapid non-enzymatic hydrolysis to the 
inactive TxB2. The synthesis of the endoperoxides and TxA2 during platelet activation 
leads to secretion of the contents of the dense granules.. TxA2 exerts its action through 
the specific G protein-coupled TxA2 receptor (TP). The TP receptor is a member of the 
G-protein-coupled receptor superfamily, which in turn regulates several effectors, 
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including phospholipase C, guanine nucleotide exchange factor of the small G protein 
Rho (RhoGEF). TP is expressed in various tissues such as platelets, endothelial cells, 
smooth muscle cells, monocytes, macrophages, kidney, heart and spleen cells.   
 
Figure 1.4. The arachidonic acid, prostaglandins and thromboxane pathway 
Thromboxane pathway. PLA2, phospholipase A2; COX-1, cyclooxygenase-1; COX-2, 
cyclooxygenase-2; TXS, thromboxane synthase; PGH2, prostaglandin H2; TxA2, 
thromboxane A2; TXB2, thromboxane B2. 
1.4.5 cyclic AMP 
The activation of blood platelets at sites of vascular injury is critical to haemostasis and 
prevention of blood loss, but, if unregulated, can lead to pathological thrombosis. To 
moderate excessive activation and return platelets to their quiescent state after transient 
activation, platelets are inhibited by endothelium-derived nitric oxide (NO) and PGI2 
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(prostaglandin I2, also known as prostacyclin). NO and PGI2 regulate multiple aspects of 
platelet function by triggering cGMP-dependent and cAMP-dependent  signaling 
pathways respectively. Elevated cAMP is associated with reduced platelet aggregation 
and diminished accrual of platelets at sites of vascular injury26.  
ACs (adenylate cyclases) belong to a family of ubiquitously expressed transmembrane 
proteins that synthesize cAMP upon activation. In platelets, ligation of GPCRs by some 
prostaglandins aor adenosine leads to AC-mediated elevation of intracellular cAMP.  
The foremost effector of cAMP in platelets is PKA (protein kinase A), which can inhibit 
platelet function by targeting several pathways of platelet activation.  s27. cAMP is a 
critical intracellular second messenger provided with strong inhibitory activity on platelet 
functions28.  
 
Figure1.5. Mechanism of antiplatelet action via cAMP levels. 
1.5 Hemorrhagic complications in MDS 
Hemorrhagic complications are among the major causes of death in MDS patients, 
particularly in those who progress to AML. In the MDACC chart review, 968 patients 
with MDS died without progression to AML. Of these, 460 patients had a coded cause of 
death: hemorrhage was a contributory cause death in 90 patients (20%) and was listed as 
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the only cause of death in 48 patients (10%)29. Other studies reported that hemorrhagic 
complications account for about 14%--45% of deaths in patients with MDS. 
Both thrombocytopenia and platelet dysfunction contribute to hemorrhagic complications 
observed in MDS30,31. The estimated prevalence of thrombocytopenia in MDS ranged 
from 40% to 65%32, but also patients without thrombocytopenia are at increased risk of 
bleeding because the risk of bleeding in MDS patients is typically attributed to both low 
platelet counts and abnormalities of platelet function33.  
Another evidence that the increased of risk of bleeding is not related to thrombocytopenia 
is that the frequency of fatal bleeding was evenly distributed among all four International 
Prognostic Scoring System (IPSS) risk groups34. The IPSS is used widely to predict 
survival and progression to AML and the platelet count is one of the four parameters 
evaluated35.   
To our knowledge the platelet count at which MDS patients with thrombocytopenia 
become at risk of hemorrhage has not been defined well. Some studies observed platelet 
hypo-reactivity in MDS patients, when stimulated with both weak and strong agonists. 
Merrelman 2000 studied 68 MDS patients and reported that MDS patients have reduced 
PA with EPI (75%), AA (54%), ADP (46%) , ristocetin (22%)36. Using impedance and 
lumiaggregometry, Manoharan et al found that, among 48 MDS patients, 35(73%) had at 
least 1 abnormal result indicating platelet hypoactivity; 7(15%) patients had mixed 
platelet hypoactivity and hyperactivity; and 4(9%) patients had platelet hyperactivity37. 
Bellucci S et al showed that one MDS patient had normal platelet expression of GPVI, 
normal binding of convulxin to platelets, but no platelet aggregation or secretion induced 
by convulxin38. 
Therefore, although there are some reports showing decreased platelet function in MDS 
patients, large studies exploring platelet function in MDS patients in depth are lacking
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We aimed at exploring several parameters of platelet function in MDS patients, including 
the regulation of platelet function by cAMP. 
3.Subjects 
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The following groups of subjects were enrolled in the study: 
 Healthy subjects 
 MDS patients 
 ITP patient 
All subjects were eligible for enrolment in the study, based on the following inclusion 
criteria 
 over 18 years of age 
 free of drugs known to affect hemostasis (e.g. non-steroidal anti-inflammatory 
drugs, ticlopidine, dipyridamol, warfarin) in the two weeks before blood sampling 
 no ischemic events or revascularization procedures not less than 3 months before 
 no drug or alcohol abuse  
Diagnoses of MDS and ITP were made based on standardized criteria.
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4.1 Blood sampling 
Blood samples were collected in the morning by venipuncture of the antecubital vein with 
a 21-gauge butterfly needle, the tourniquet released soon after needle insertion. The first 
3 mL of blood was collected into K3EDTA (Sarstedt, Verona, Italy) for blood cell count 
MEDONIC CBC counter immediately following the blood draw. Subsequent 30mL blood 
was drawn with a polypropylene (PP) syringe (10 ml) and transferred immediately into 
three PP tubes containing sodium citrate anticoagulant solutions (109 mM, 1:9 v/v, final 
volume 10 ml), gently mixed, allowed ‘to rest’ at room temperature (RT) for 15 min, and 
centrifuged to obtain platelet-rich plasma (PRP)1. Blood samples for preparation of serum 
were collected into tubes without anticoagulant, and another 3mL of whole blood were 
collected into tubes of 3.2% citrate (Sarstedt, Verona, Italy) for flow cytometery. For the 
flowcytometry measurement of P-selectin, immediately after blood sampling, 4uL of 
proteinase inhibitors was added to 400uL of fresh whole blood, mixed gently, then take 
200uL of the mixture added into 400uL PAMFIX(Vpamfix: Vblood=2:1), store at 4℃ 
overnight.  
 4.2 Light transmition aggregometry 
Platelet aggregation was measured by light transmission aggregometry (LTA) using 
Chrono-Log 560 (Havertown, PA, USA).  Platelet rich plasma (PRP) was obtained by 
centrifugation of citrate whole blood samples at 200 x g for 10 min at room temperature. 
Autologous platelet-poor plasma (PPP) was obtained by centrifugation of blood samples 
at 1.400 x g, at room temperature for 15 min. Autologous PPP was used to set the 
instruments’ 100% light transmission, while un-stimulated PRP was used to set 0% light 
transmission. The individual platelet count of the PRPs was not adjusted to a pre-
determined range, because this procedure may induce artefacts. All aggregation tests were 
performed within 3 hours after blood collection. 
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Samples of PRP (225 µL) were pre-warmed at 37°C for 3 minutes, then incubated with 
25 µL luciferine/luciferase reagent at 37°C for 30 seconds and stirred at 1000 rpm in a 
lumi-aggregometer. After incubation, 5 uL of an aggregating agent was added, including 
ADP (2 or 4 or 20µM), epinephrine (5 or 10 µM), thrombin receptor active peptide (TRAP) 
(10 or 20 µM), synthetic liquid reactive peptide (SRP) (4 or 8ng/mL), collagen reactive 
peptide (CRP) (0.1 or 1 or 10µg/mL), Horm collagen (2, 4 or 10 µg/mL) and arachidonic 
acid (AA) (1 mM). Changes in light transmission (caused by the formation of platelet 
aggregates) were recorded for 3min. At the same time, ATP secretion tracings were 
recorded.  
In addition, Prostaglandin E1 (PGE1) (0.1µM) response was tested in collagen induced 
platelet aggregation. PGE1 was incubated with PRP for 30 seconds before the addition of 
luciferase, after another 30 seconds incubation with luciferase, collagen was added to 
stimulate platelets aggregation. Maximal aggregation response to each agonist was 
measured and expressed as percent increase in light transmission.  
Standard linear curve for ATP release measurement was made using the following 
concentrations of ATP: 2nM, 1 nM, 0.5 nM, 0.25 nM, 0.125 nM.  
4.3 Delta granules contents measurement of ATP and ADP 
1mL fresh PRP was mixed with 50µL 100mM EDTA and 950µL absolute Ethanol, then 
centrifuged at 16000g for 45mins at 4°C; the supernatant was stored at -80°C until 
analysis.  
Nucleotide measurement adopted the firefly luciferin-luciferase system (Roche), used 
lumi-aggregometer Chrono-Log 560. Practically, add 30µL luciferase was added into 
267.5µL buffer (4.5mM potassium acetate, 3.4mM EDTA, 0.09M TRIS-acetate), after 
incubation for 30 seconds, curves were made by 2.5µL of extracted samples, followed by 
25pmol ATP. Light output by samples was proportional to the concentration of ATP. 
Subsequently, ADP was converted to ATP by the addition of pyruvate 
kinase/phosphoenolpyruvate (PK/PEP). ADP and ATP contents were expressed as pmoles 
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per 10^8 platelets. 
Analysis of results: 
The output is a unit of light emission. Then the results from ATP standard are used to 
determine the amount of ATP and ADP using the following formula: 
STD (mm) : STD (mol) = R (mm) : R (mol)                 (4.1) 
Where: STD = ATP standard; R= Results that we are looking for. 
 Using an ATP standard of 5 µL of 5 µM solution, 25 pmol are added to the solution  
 The sample added has a dilution of ½ during preparation (see methods). (We add 2.5 
µL in the reaction system) 
R(mol) = [R(mm)*STD(mol)] / STD(mm)=I1  /  S1* 25 pmol          (4.2) 
R(concentration) = 25pmoli / 2.5µL * I1 / S1*2= 20* I1 / S1         (4.3) 
This is the formula that can convert the result obtained by instrument in 
concentration of our interest, where 5 is a conversion factor. 
 If 2.5 µL of diluted sample at 50% was added, the conversion factor is 40. 
4.4 Flow Cytometry Measurements  
The presence of platelet specific antigens was analyzed in citrated whole blood of normal 
platelets and from patients diagnosed with platelet abnormalities, using a gating strategy 
based on ubiquitously expressed platelet membrane markers. We were able to detect the 
platelet antigens GPVI, CD41, CD42a, CD42b and CD61 in one single tube. 
CD62P PhycoErythrin(PE) 
The AK-4 monoclonal antibody specifically binds to CD62P. CD62P is a 140 kDa type I 
transmembrane glycoprotein that is also known as P-Selectin, Platelet activation-
dependent granule membrane protein (PADGEM), or GMP-140. P-Selectin is stored in 
the α-granules of platelets and the Weibel-Palade bodies of endothelial cells, and is 
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rapidly transported to the plasma membrane upon activation. P-Selectin is thought to 
mediate the initial adhesive interactions of neutrophils and monocytes with endothelium 
in inflammatory responses, and of activated platelets to neutrophils and monocytes in 
hemostasis. 
CD41 Fluorescein isothiocyanate (FITC) 
The CD41 antigen is the integrin αIIb chain, also called platelet gpIIb. The molecular 
weight of the recognized antigen is 135 kDa. CD41 is non-covalently associated with the 
integrin β3 chain, also called gpIIIa or CD61. The P2 monoclonal antibody (mAb) reacts 
with gpIIb in the intact complex with gpIIIa, but not with gpIIb or gpIIIa separately  
CD42a Fluorescein isothiocyanate (FITC) 
The CD42a antigen (GPIX) is a transmembrane glycoprotein of 22 kDa which forms a 
non-covalent complex with CD42bc (GPIb) and CD42d (GPV). CD42a expression is 
restricted to platelets and megakaryocytes. The SZ1 monoclonal antibody reacts with 
CD42a only within the intact CD42a-d complex 
CD42b Allophycocyanin (APC) 
The HIP1 monoclonal antibody specifically binds to CD42b. CD42b is also known as the 
Platelet glycoprotein Ib alpha chain that is encoded by the GP1BA gene. CD42b is 
disulfide bonded to CD42c to form a 170 kDa heterodimer, GPIb. GPIb forms a 
noncovalent complex with CD42a and CD42d (CD42 complex) that is expressed on 
platelets and megakaryocytes. The CD42 complex serves as the von Willebrand 
Factor(vWF) surface receptor involved in the adhesion of platelets to the subendothelium 
of damaged vascular walls. HIP1 inhibits the ristocetin-dependent binding ofvWF to 
platelets and partially inhibits collagen-induced aggregation 
CD61 phycoerythrin (PE) 
The VI-PL2 monoclonal antibody specifically binds to CD61. CD61 is a 105 kDa 
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transmembrane glycoprotein that is also known as integrin β3 and platelet glycoprotein 
IIIa (GPIIIa or GP3A). It is expressed on platelets, megakaryocytes, osteoclasts and 
endothelia. Integrin β3 associates with gpIIa (CD41) to form the CD41/CD61 complex 
which mediates platelet adhesion and aggregation. CD61 also associates with CD51 to 
form the CD51/CD61 complex (vitronectin receptor). CD61 appears to bind to fibrinogen, 
fibronectin, vWF, vitronectin, and thrombospondin to mediate cell adhesion.  
GPVI phycoerythrin (PE) 
This CLONE 1G5 antibody recognizes the human Glycoprotein VI (GpVI)  GpVI is a 
62 kDa type 1 transmembrane receptor belonging to the immunoglobulin superfamily, 
and noncovalently associated with the signal-transducing FcRγ chain. GpVI is a major 
collagen receptor that plays a crucial role in the collagen-induced activation and 
aggregation of platelets. As well as collagen, other ligands such as collagen-related 
peptide (CRP) and snake venom protein (convulxin) can bind to the extracellular region 
of GpVI causing ectodomain shedding. This process is tightly regulated by a 
metalloproteinase, most likely ADAM10, providing a mechanism for the modulation of 
platelet responsiveness. Most GpVI is maintained in a monomeric form on resting 
platelets. GpVI dimerization is a cAMPcontrolled active process that primes platelet 
interaction with fibrillar collagen. 
PAMFix (Platelet Solutions Ltd, Nottingham) 
PAMFix was developed as a one-step procedure for stabilising platelets in blood for 
measurement of platelet activation markers (PAM) on the surface of platelets such as P-
selectin (CD62P) from α-granules. It is also useful for measuring CD63 from dense bodies 
in platelets. PAMFix stabilises activation markers on the surface of platelets so that 
analysis can be performed up to 9 days following sample preparation. This enables remote 
testing of platelet function. 
 
Figure 4.1. One-step procedure for stabilising platelets 
4.Methods 
31 
 
Samples were analysed by using FACSverseTM BD FACS verse 6 color flow cytometry. 
Calibration beads automate the characterization of cytometer fluorescence detectors and 
the entire optical configuration by creating baselines with performance values, which 
have to be targeted prior to each measurement to ensure standardized performance. 
BD FACSuite™ software controls the connection between the flow cytometer and 
instruments being the platform to perform calibration and acquisition.  
All samples were acquired with a slow flow rate, and for each samples 5000 events were 
recorded.  
4.4.1 Detector settings for rest platelets surface receptors 
A set up experiment was made with a FS-log/SS-log plot and all fluorochrome 
combinations (FITC/PE, FITC/APC, PE/APC). FS and SS etectors where set to log-
scale for detection of small particles. An unstained sample was used to adjust the FS/SS 
PMT voltages to a level that red blood cells and platelets could be separated and gated 
(Figure. 4.2). 
 
 
Figure 4.2. P1: FS-log/SS-log plot set for distinguish of platelet cloud 
Gating platelets in P1, the double fluorochrome dot plots allow adjusting FL voltages to 
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a sensitivity level that all unstained platelets were negative. (Figure 4.2). 
 
Figure. 4.3(a). Double fluorochrome dot plots to determine the purity of the platelet 
population. (CD61-PE) 
 
 
Figure. 4.3(b). Double fluorochrome dot plots to determine the purity of the platelet 
population.(CD42b -APC)  
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To detect the optimal antibody concentration, titration assays were performed with a fixed 
number of platelets (1*10^9). Settings were checked with proper fluorochrome and 
isotype matched controls.  
The gating strategy determines the purity of the platelet population in whole blood. A 
variety of small particles can contaminate the platelet selection when the forward scatter, 
side scatter approach is used. These contaminations, do not express CD61 or CD42b. A 
proper platelet selection (>99%) can be performed by gating for platelet antigens that are 
ubiquitously present at platelet membrane such as CD61 and CD42b (Figure. 4.3). 
4.4.2 Detector settings for rest platelets surface p-selectin expression 
By using a dot plot CD42b-APC vs CD62P-PE, we plotted cells gated in “platelet” and 
we defined the positive cells basing on isotype control. We fixed the isotype control at a 
maximum of 4% of positive to CD62P cells. The analytic parameter used to evaluate the 
level of P-selectin expression was always the % of cells positive to the antibody CD62P. 
 
 
Figure 4.4. Detect of P-selectin by flow cytometer: isotype control and sample 
The monoclonal antibody CD62P PE was used to detect P-selectin. 400μl Fresh cirate 
anticoagulated whole blood was treated with protease inhibitors (sigma), then added 2 
times volumes of PAMFIX and mixed gently, stored at 4℃ degree overnight. 5μl of fixed 
samples mixed with 45μl PBS and antibodies then determined by flow cytometry. 
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4.5 TXB2 levels 
Serum was prepared from non-anticoagulated venous blood that was allowed to clot at 
37°C for 1 hour, centrifuged at 1,400 x g at RT for 15 min, and stored at -80°C until assay. 
TxA2 levels are typically monitored by measurement of its stable metabolite TxB2, which 
we measured by using a selective, competitive enzyme immunoassay (Thromboxane B2 
EIA kit, Cayman Chemical Company, Ann Arbor,MI, USA). Frozen samples were thawed 
at 37°C and diluted between 1:2 and 1:3000 with buffer and tested in duplicate. The plate 
was read at 405 nm wavelength in a standard 96-well plate reader (Ensight). Samples 
were assayed in parallel with known TxB2 standards, prepared as outlined in the 
manufacturer’s instructions, and a maximum binding control. The percent binding of 
known standards was calculated in reference to the maximum binding controls, plotted 
against the logarithm of concentration and analyzed by non-linear regression. Unknown 
samples were expressed in a similar fashion, interpolated from this standard curve and 
corrected for dilution. Samples with results outside the standard curve were re-assayed 
with appropriate dilution. The detection limit of the assay is 11 pg/mL. Data are expressed 
as pmoles/108 platelets. 
4.6 cAMP levels 
Platelet cAMP was measured by an ELISA assay, using a commercially available kit 
(Cyclic AMP Select ELISA Kit; Item No.501040, USA). Duplicate samples of 500µL 
citrated PRP containing 1 mM theophylline were incubated with Tyrode’s buffer and 
PGE1 (1 µM), PGE1 (0.1 µM), or Tyrode’s buffer alone in a control mixture. After 
incubation at 37°C (2 minutes), 500µL of 5% trichloroacetic acid added, samples were 
snap-frozen in liquid Nitrogen. Thawed them at ambient temperature, and rotated at 4°C 
for 45 minutes, followed by centrifugation at 4°C for 30 minutes, the supernatant was 
extracted with one volume of Trioctylamine as well as 2.5 volume of DCM, vortex for 2 
min and then centrifuge at 3,000g for 15min, collect supernatant and store in -80 degree. 
When dosage by ELISA, Samples were thaw at room temperature and diluted with EIA 
buffer before assay. Samples of PPP with theophylline and Tyrode’s buffer were also 
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collected, which should be subtracted for calculation to make sure all the cAMP from 
platelets. 
4.7 Serotonin levels 
Platelet serotonin was measured by Fluorescence spectrophotometry. 
400μL of EDTA 0.1M was added into 1mL PRP, mix gently by inverting the Eppendorf 
several times, and then centrifuge at 12,000g for 3 minutes at room temperature, discard 
all the supernatant and make pellet dry for one hour, then froze at -80°C until dosage. 
Thaw the pellet samples at room temperature, add 500uL of 10% TCA, homogenize and 
vortex, centrifuge for 2 minutes at 12000 rpm, transfer 400 L of supernatant to 10 mL in 
glass tubes with screw cap. Add 1.6 mL of OPT / HCl and vortex. Boil for 10 minutes, 
cool to RT, Add 5 mL of saturated dichloromethane (DCM) under the hood, vortex until 
separate well. Transfer 200μL of supernatant in a 96wells plate. Transfer 400μL standard 
of 4μM 5HT, 2μM, 1μM and 200 nM in 10mL glass tubes with screw cap, and treated the 
same as samples. Make a blank with 400 μL 10% TCA and treat it as the champions. Read 
by EnSight™ Multimode Plate Reader from PerkinElmer. 
4.8 PF4 levels 
20uL of Triton 20% was added into 400uL PRP, mix by inverting the Eppendorf several 
times, and froze the samples at -80°C until dosage. PF4 was measured by Elisa (Human 
CXCL4/PF4 PicoKine ELISA Kit, BSR-EK0726, BOSTER, CANADA). Results were 
expressed as ng/106 platelets.
5.Results 
 
 
 
5.Results 
 
 
 
 
 
 
 
5.Results 
37 
 
5.1 Population characteristics 
Thirty two MDS patients and 26 ITP patients, as well as 54 healthy subjects were enrolled 
in this study 
Clinical data 
MDS: Characteristics of MDS patients are presented in Table 5.1.  
Table 5.1. Characteristics patients with MDS 
Patient Characteristics N(%)  
 ALL MDS 
patients  
PLT/PRP>100,000 
per µL,  
No anti-platelet 
drug  
AGE 
<55 yrs. 0 0 
55-64 yrs. 1 1 
65-74 yrs. 9 3 
>75 yrs. 22 10 
SEX 
Female 10 8 
Male 22 6 
 
 
 
 
WHO 
MDS-RA 6 3 
MDS-RARS 1 0 
MDS-LMMC 6 3 
MDS-RCMD 4 1 
MDS-RAEB-1 11 5 
MDS-RCMD-RS 0 0 
MDS-RAEB-2 1 0 
MDS-U 2 0 
MDS-5q 1 1 
 
 
IPSS 
Low 15 5 
Int1 11 6 
Int2 2 1 
High 1 1 
Unknown 3 0 
 
 
 
R-IPSS 
Very low 2 5 
Low 9 6 
Intermediate 7 1 
High 2 1 
Very high 0 0 
Unknown 11 5 
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Karyoty 
Good 19 6 
Intermediate 8 1 
Poor 4 1 
Unknown 1 0 
 
 
 
 
Karyotype 
-7/del(7q) isolated or 
+1 
1 1 
del(20q) isolated 1 1 
del(5q) isolated 1 1 
+8 isolated 1 1 
Complex 3 2 
Normal 17 4 
-Y 3 2 
OTHER 4 2 
Unknown 1 0 
 
 
Blast % 
< 5 % 6 3 
5–10 14 7 
11–20 % 3 0 
21–30 % 0 0 
Unknown 9 4 
 
 
Hemoglobin (g/dl) 
< 8.0 3 3 
8.0 – 9.99 7 7 
10.0 – 11.99 8 0 
≥12.0 14 0 
Unknown 0 4 
 
Absolute Neutrophil 
Count (cells/µL) 
< 500 0 3 
500 – 1,499 0 7 
1,500 – 9,999 28 0 
≥10,000 3 0 
Unknown 1 4 
 
 
Platelets (per µL) 
< 50,000 3 3 
50,000 – 149,000 15 7 
150,000 – 449,999 13 0 
≥ 450,000 1 0 
Unknown 0 4 
Time from diagnosis 
to PLT funtion 
Mean months 33.14±24.41 32.61±37.70 
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 Table 5.2. Blood cell counts in three groups 
 Healthy 
subjects 
MDS 
Patients 
ITP 
Patients 
p p p 
 (mean ± DS) (mean±DS) (mean±DS) Healthy 
vs MDS 
Healthy 
vs ITP 
MDS 
vs ITP 
WBC 
(103/µL) 
6,953 ± 1,956 7,168±6,155 7,467±2,463 NS NS NS 
RBC 
(106/µL) 
4,744±0,545 3,927±1,211 4,581±0,603 < 0,0001 NS 0,006 
Hgb(g/dL) 13,84±1,56 11,38±2,48 13,43±1,59 < 0,0001 NS 0,0035 
Hct(%) 41,15±4,41 36,64±12,17 40,22±5,08 < 0,0001 NS 0,0038 
MCV (fL) 87,02±6,63 88,18±20,46 88,09±5,77 0,0427 NS NS 
MCH (pg) 29,32±2,90 30,45±4,52 29,47±1,97 NS NS NS 
MCHC 
(g/dL) 
33,73±2,81 32,54±2,99 33,47±1,05 0,0213 NS NS 
PLT 
(103/µL) 
229,1±42,48 152,9±111,9 76,52±48,30 < 0,0001 < 0,0001 0,0185 
MPV (fL) 8,62±0,92 8,69±1,48 10,27±1,56 NS 0,0001 0,0011 
 
5.2 Platelet aggregation and secretion 
Because measurement of platelet aggregation by LTA may be inaccurate at platelet counts 
in PRP lower than 150*10^3/µL, we excluded from the analysis patients whose PRP 
platelet counts were lower than 150*10^3/µL  
Patients on treatment with antiplatelet agents were also excluded from the analysis 
Overall, data from 50 healthy subjects, 14 MDS patients and 11 ITP patients were 
available for statistical analysis (Dunn's multiple comparisons test). 
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5.2.1 ADP 2µM-induced platelet aggregation and secretion 
The percentage of platelet aggregation after ADP 2uM stimulation showed significantly 
difference between healthy subjects and MDS patients, while ITP group showed no 
difference with any of the other two groups.  
For ATP secretion, the method did not have limitation for platelet count, so for statistics, 
only data from patients who undergo antiplatelet therapy were excluded. Data from 50 
healthy subjects, 21 MDS patients and 25 ITP patients were analyzed statistically, using 
Dunn's multiple comparisons test. Results showed both MDS and ITP groups were 
signigicantly lower than healthy subjects.  
 
Figure 5.1. Adenosine Diphosphate 2µM induced platelet aggregation and secretion 
5.2.2 Epinephrine 5µM-induced platelet aggregation and secretion 
The same trend was observed when platelets were stimulated by Epinephrine at final 
concentration 5uM. The percentage of platelet aggregation was significantly lower in 
MDS patients than healthy subjects, while ITP group showed no difference with any of 
the other two groups.   
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ATP secretion was significantly lower in MDS and ITP groups than in healthy subjects. 
There was no statistically significant difference between MDS and ITP groups.  
 
Figure 5.2. Epinephrine 5µM induced platelet aggregation and secretion 
5.2.3 Thrombin receptor activator peptide (TRAP) 10µM induced platelet agg
regation and secretion 
The same trend was observed when platelets were stimulated by TRAP at final 
concentration 10uM. The percentage of platelet aggregation was significantly higher in 
healthy subjects compared to MDS patients.  
ATP secretion was significantly lower in both MDS and ITP than in healthy subjects, 
There was no statistically significant difference between MDS and ITP groups.  
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Figure 5.3. TRAP 10µM induced platelet aggregation and secretion 
5.2.4 Collagen 2µg/mL-induced platelet aggregation and secretion 
When platelets were stimulated by collagen at final concentration of 2µg/mL, the 
percentage of platelet aggregation was significantly lowers in MDS patients than in 
healthy subjects, while no statistically significant differences were observed between ITP 
and the other groups. 
ATP secretion was lower in both MDS and ITP patients compared to healthy controls. 
There was no statistically significant difference between MDS and ITP patients. 
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Figure 5.4. Collagen 2µg/mL induced platelet aggregation and secretion 
5.2.5 SRP 4ng/mL and CRP 0.1µG/mL induced platelet aggregateion and  
secretion 
We did LTA tests also for Synthetic Liquid Reactive Peptide SRP (final concentration 
4ng/mL) and Collagen reactive peptide CRP (final concentration, 0,1µg/mL), they are 
two agonists specific for GPVI, one of the receptors for collagen. 
After stimulating with SRP, platelet aggregation in MDS and ITP groups were both 
significantly lower than in healthy subjects. Platelet ATP secretion showed the same trend, 
because it was significantly lower in MDS and ITP patients than in healthy subjects. 
CRP-induced platelet aggregation and ATP secretion in MDS and ITP patients were also 
significantly lower than in healthy subjects..  
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Figure 5.5. SRP 4ng/mL induced platelet aggregation and secretion 
 
Figure 5.6. CRP 0,1ug/mL induced platelet aggregation and secretion 
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5.2.6 Arachidonic acid-1mM induced platelet aggregation and sec-retion 
Arachidonic acid (1mM)-induced PA was significantly lower in MDS patients than in 
healthy subjects, while ATP secretion was lower in both MDS and ITP patients compared 
to healthy subjects. There was no statistical difference between MDS and ITP groups. 
 
Figure 5.7. Arachidonic acid-1mM induced platelet aggregation and sec-retion 
5.3 Inhibitory effect Prostaglandin E1 on collagen-induced platelet 
aggregation and secretion  
Prostaglandin E1 inhibited collagen-induced platelet aggregation by 32.61%, 55.20%, 
25.72% in healthy subjects, MDS patients and ITP patients respectively.  Kruskal-Wallis 
test of Dunn's multiple comparisons test showed the decrease of platelet aggregation was 
statistically significant in MDS group compared with healthy subjects, while ITP patients 
showed no difference with the other two groups. In other words, platelets from MDS 
patients were more sensitive to Prostaglandin E1 than the other two groups. However, the 
decrease of ATP secretion were similar among the three groups. 
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Figure 5.8.  Inhibitory effect Prostaglandin E1 on  
collagen induced platelet aggregation and secretion 
  5.4 Platelet granules content 
5.4.1. ATP and ADP 
There was no statistically significant differences in the platelet ATP content among the 3 
groups (Figure 5.9 a).  
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Figure 5.9 a. ATP contents in delta granules among three groups 
In contrast, the platelet ADP content in MDS patients was significantly lower than in 
healthy subject(Figure 5.9 b). There was no statistically significant differences between 
ITP patients and any of the other two groups. However, the ratio between ATP and ADP 
was significantly higher in both MDS and ITP groups than in the healthy subjects 
group(Figure 5.10). 
 
Figure 5.9 b. ADP contents in delta granules among three groups
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Figure 5.10.  ATP/ADP RATIO among three groups 
5.4.2 Platelet serotonin levels 
Both MDS and ITP patients had lower levels of platelet serotonin than 
healthy subjects (Figure 5.11). 
 
Figure 5.11. Serotonin level in delta granules 
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5.4.3. Platelet factor 4 levels 
Both MDS and ITP patients had lower levels of PF4 than healthy subjects 
(Figure 5.12). 
 
Figure 5.12. Platelet factor 4 level in alpha granules 
5.5 Flow cytometry measurement of expression of surface receptors on 
resting platelets 
Mean fluorescence intensity for CD41 and CD61 was similar in the three groups of 
subjects. However, CD42a expression was significantly higher in ITP patients than in the 
other two groups of subjects; CD42b and GPVI were higher in ITP than in MDS (Figure 
5.13). P-selectin expression was similar among three groups (Figure 5.14). 
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Figure 5.13. Comparison of platelet surface receptors expression  
 
C D 4 1
A
M
F
I
C
T
R
L
 
M
D
S
I T
P
0
2 0 0 0
4 0 0 0
6 0 0 0
8 0 0 0
1 0 0 0 0
C D 6 1
B
M
F
I
C
T
R
L
 
M
D
S
I T
P
0
2 0 0 0
4 0 0 0
6 0 0 0
8 0 0 0
C D 4 2 a
C
M
F
I
C
T
R
L
 
M
D
S
I T
P
0
2 0 0 0
4 0 0 0
6 0 0 0
8 0 0 0
*
*
p = 0 . 0 0 9 9
p = 0 . 0 1 3 2
C D 4 2 b
D
M
F
I
C
T
R
L
 
M
D
S
I T
P
0
5 0 0 0
1 0 0 0 0
1 5 0 0 0
2 0 0 0 0
* *
p = 0 . 0 0 9 8
G P V I
E
M
F
I
C
T
R
L
 
M
D
S
I T
P
0
5 0 0
1 0 0 0
1 5 0 0
*
p = 0 . 0 3 4 1
5.Results 
51 
 
 
Figure 5.14. Comparison of rest platelet surface p-selectin expression 
5.6 Serum TxB2 levels  
Serum TxB2 levels in MDS patients were significantly lower than in healthy subjects, 
p=0.0153 (Figure 5.15), while there was no statistically significant differences between 
ITP patients and the other two groups of subjects. 
 
Figure 5.15. Serum TxB2 level comparison in three groups. 
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5.7 Platelet cAMP levels 
We measured cAMP levels from 54 healthy subjects, 32 MDS patients and 26 ITP patients, 
including cAMP levels in platelet poor plasma, platelet rich plasma, and also in PGE1 
stimulated platelet rich plasma. To calculate platelet cAMP level, we substract PPP cAMP 
from PRP cAMP, then divided by the count of platelet in PRP. 
5.7.1 Baseline PPP levels of cAMP 
There was no statistically significant difference of cAMP level in platelet poor plasma 
between among the study groups (Figure 5.16).  
5.7.2 Baseline PRP levels of cAMP 
There was no statistically significant difference of cAMP level in PRP between among 
the study groups (Figure 5.16). 
5.7.3 PRP levels of cAMP after PGE1 stimulation 
In the presence of Prostanglandin E1 (0.1 or 1.0 uM), cAMP levels in MDS and ITP 
patients were significantly lower than in healthy subjects; there was no difference 
between ITP and MDS patients (Figure 5.16).  
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Figure 5.16. Total cAMP level (pmol/mL) comparisons in three groups 
5.7.4 Platelet levels of cAMP pmol/10^9PLT 
The intraplatelet levels of cAMP at baseline and in the presence of PGE1 0.1 or 1.0 uM 
were similar in the three groups of subjects. 
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Figure 5.17. platelet cAMP level (pmol/10^9PLT) comparisons in three groups 
5.7.5 Increase of cAMP concentration regard to platelet poor plasma level 
The increase of cAMP was calculated as RATIO of the cAMP concentration in (PRP – 
PPP)/PPP.   
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Figure 5.18. Increase of cAMP concentration regard to platelet poor plasma level 
Three was no statistically significant difference in the baseline intraplatelet cAMP 
between MDS and healthy subjects, while lower levels were observed in ITP patients. In 
the presence of PGE1 0.1 or 1.0 uM, intraplatelet cAMPO levels were higher in healthy 
controls than in the other two groups of patients. (Figure 5.18).
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Documented evidence indicate that both thrombocytopenia and platelet dysfunction 
contribute to hemorrhagic complications observed in MDS, which account for 14-45% 
of deaths2 . Bleeding in such patients is often attributed to the low platelet count, 
although in many patients platelet qualitative defects play an important role; a recent 
review of 838 MDS patients suggested qualitative rather than quantitative platelet 
abnormalities have prognostic significance8. A detailed study of the clinical features of 
2900 patients with MDS reported that even among patients with platelet 
counts >50,000/uL, 19% had signs of bleeding at the time of diagnosis39.  
Several studies explored platelet aggregation by LTA or platelet activation by flow 
cytometry, platelet granules contents and the expression of surface receptors in MDS 
patients, reporting contradictory results40. In this study we aimed at exploring several 
parameters of platelet function in MDS patients, including the regulation of platelet 
function by cAMP, comparing it with normal controls and patients with ITP and 
comparable platelet counts as MDS patients.  
The main results of our study can be summarized as follows: 1) platelet aggregation 
induced in PRP by all tested agonists was significantly lower in MDS patients than in 
both control groups, while there was no difference between ITP and healthy subjects. 
MDS and ITP patients had decreased ATP release measured during aggregation induced 
by all agonists compared to controls. 3) Platelet delta granules content of  serotonin 
and ADP, alpha granules content of platelet factor 4 were lower than in healthy subjects, 
while serotonin only was lower than also in ITP patients. 3) Inhibition of platelet 
aggregation by exogenous PGE1 was significantly higher in MDS patients than in the 
other two groups. However, cAMP induced by PGE1, (0.1uM and 1 uM) was not higher 
in MDS patients, compared to ITP and healthy controls. 4) Platelet surface expression 
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of glycoprotein receptors in MDS group was normal while it tended to be higher in ITP 
platelets (CD42a, CD42b and GPVI).  
The defect of platelet aggregation of MDS patients is not attributable to abnormalities 
of GPIIb/IIIa, the expression of which on the platelet membrane was normal. Reduced 
content of ADP in platelet delta granules, and, as a consequence, reduced ADP secretion 
during aggregation, could be responsible for the abnormal platelet aggregation in MDS 
patients. As a matter of fact, secreted ADP amplifies the platelet aggregation response 
to platelet agonists that induce platelet secretion. Reduced ADP secretion could also be 
responsible for the greater sensitivity of platelets to the inhibitory effect of external 
PGE1 on platelet aggregation, in the absence of increased platelet cAMP production, 
compared to other controls. As a matter of fact, it is known that ADP, by interacting 
with the platelet P2Y12 receptor, inhibits adenylate cyclase, the enzyme that is 
responsible for cAMP formation, which is stimulated by PGE1 (and other inhibitory 
prostaglandins) 41. Lower than normal concentrations of secreted ADP will interact 
with P2Y12, resulting in lower inhibition of adenylate cyclase and lower cAMP 
production when platelets are stimulated by a secretion-inducing agonist, in the 
presence of PGE1. It is therefore likely that, although cAMP production by platelets 
exposed to PGE1 is normal, it would likely by reduced when PGE1 is added to platelets 
that are aggregating and secreting ADP as a consequence of stimulation of agonists. 
The finding of normal platelet content at baseline and after exposure to PGE1 in MDS 
patients contrasts with our previous observations in individual MDS patients at high 
risk, whose platelets contained high baseline levels of cAMP, which were greatly 
enhanced by exposure to PGE1, even at low concentrations (0.1 uM).  Therefore, 
dysregulated cAMP production seems to be a rare finding in MDS patients, probably 
confined to patients at high risk, transitioning to acute myeloid leukemia.  
Our observation of decreased content of both delta and alpha granules in MDS patients 
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suggest that generalized abnormality in platelet granules formation is characteristic of 
the disease. An alternative explanation of increased platelet activation in vivo, with 
platelet secretion of their granules contents in the circulation resulting in the presence 
of circulating “exhausted platelets”, is unlikely because our patients did not display any 
clinically relevant evidence of vascular disease, which could have caused platelet 
activation in vivo.  
In conclusion, many MDS patients in the series that we studied displayed platelet 
dysfunction, associated with abnormalities of both delta and alpha granules, which 
could be categorized as acquired alpha-delta storage pool deficiency. Similar 
abnormalities have been described in other patient populations, such as 
myeloproliferative neoplasm and could contribute to the bleeding tendency of these 
patients.
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